This clinical trial is focused on studying a type of cancer called Marginal Zone Lymphoma (MZL), which is a form of lymphoma, a cancer that affects the lymphatic system. The study aims to compare two different imaging methods used to detect and stage this disease. The first method uses a special imaging agent called [68Ga]Ga-PentixaFor, and the second method uses another agent known as [18F]FDG. Both of these agents are used in a type of scan called PET/CT, which combines positron emission tomography (PET) and computed tomography (CT) to create detailed images of the body.

The purpose of the study is to determine if the [68Ga]Ga-PentixaFor imaging method is better at detecting cancerous lesions compared to the [18F]FDG method. Participants in the study will undergo both types of scans, and the results will be compared to see which method provides more accurate information about the presence and extent of the lymphoma. This comparison will help doctors understand which imaging technique is more effective for staging MZL and potentially other similar types of lymphomas.

Throughout the study, participants will receive the imaging agents through an intravenous injection, which means the substance is injected directly into a vein. The study will also assess the safety and tolerability of these imaging agents to ensure they are safe for use in patients. By participating in this trial, researchers hope to improve the way MZL is diagnosed and staged, ultimately leading to better treatment planning and management for patients with this condition.